This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

KEYTRUDA® (pembrolizumab) KEYNOTE-590 clinical data presentation

The KEYNOTE-590 study explores KEYTRUDA (pembrolizumab) in combination with chemotherapy for patients with locally advanced or metastatic oesophageal cancer whose tumours express a PD-L1 CPS ≥10 score. This slide deck includes information on the study design, trial endpoints, efficacy and safety.

CPS = Combined Positive Score; PD-L1 = Programmed Death Ligand 1

More information about KEYTRUDA® (pembrolizumab) in locally advanced unresectable or metastatic oesophageal cancer

Supporting documentation

By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-01617 | Date of Preparation: August 2021